Want to see GB:ABDX full AI Analyst Report?
ABDX Stock Chart & Stats
6.25 p
0.20 p(2.50%)
At close: 4:00 PM EST
6.25 p
0.20 p(2.50%)
Day’s Range― - ―
52-Week Range5.10 p - 13.00 p
Previous CloseN/A
Volume7.61K
Average Volume (3M)78.74K
Market Cap
£24.64M
Enterprise Value22.52 p
Total Cash (Recent Filing)£3.71M
Total Debt (Recent Filing)£948.00K
Price to Earnings (P/E)―
Beta-0.08
Next Earnings
Nov 18, 2026EPS Estimate
<0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding252,751,500
10 Day Avg. Volume45,332
30 Day Avg. Volume78,736
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)4.84
Price to Sales (P/S)3.04
P/FCF Ratio-7.48
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)<0.01
Revenue Forecast (FY)£15.22M
Bulls Say, Bears Say
Bulls Say
Revenue GrowthSustained high revenue growth reflects expanding commercial traction for Abingdon's rapid diagnostics and services. Over a 2–6 month horizon this underpins higher factory utilization, broader customer engagement, and the potential to convert scale into more predictable, recurring B2B contract revenue streams.
B2B Contract Manufacturing ModelA fee-for-service R&D and contract manufacturing model yields diversified, program-linked revenue rather than retail volatility. Durable customer relationships and volume-based contracts support repeat business and predictable production runs, enabling operational scale and long-term revenue visibility when execution is steady.
Manageable LeverageRelatively low debt provides financial flexibility to fund working capital, capacity builds, and product development without immediate refinancing pressure. This balance sheet headroom reduces bankruptcy risk and supports multi-month contract performance and strategic investments over the medium term.
Bears Say
Negative Operating Cash FlowSustained negative operating cash flow indicates difficulty converting revenues into cash from core operations, forcing dependence on external financing or equity raises. This constrains reinvestment in capacity, R&D, and working capital, and raises dilution or interest burden risks over the coming months.
Declining Gross MarginA falling gross margin signals rising unit costs or pricing pressure in test manufacture. Margin erosion limits the company's ability to translate revenue growth into profitability, weakening scale economics and requiring structural cost controls or pricing power to restore sustainable margins.
Negative Return On Equity / Ongoing LossesNegative ROE and continued losses show the business is not delivering returns on invested capital, increasing the likelihood of further capital raises. That dynamic can dilute shareholders, limit strategic optionality, and constrain the firm's ability to fund growth internally across the next several quarters.
Abingdon Health PLC News
ABDX FAQ
What was Abingdon Health PLC’s price range in the past 12 months?
Abingdon Health PLC lowest share price was 5.10 p and its highest was 13.00 p in the past 12 months.
What is Abingdon Health PLC’s market cap?
Abingdon Health PLC’s market cap is £24.64M.
When is Abingdon Health PLC’s upcoming earnings report date?
Abingdon Health PLC’s upcoming earnings report date is Nov 18, 2026 which is in 119 days.
How were Abingdon Health PLC’s earnings last quarter?
Abingdon Health PLC released its earnings results on Mar 17, 2026. The company reported -0.004 p earnings per share for the quarter, beating the consensus estimate of -0.006 p by 0.002 p.
Is Abingdon Health PLC overvalued?
According to Wall Street analysts Abingdon Health PLC’s price is currently Overvalued.
Does Abingdon Health PLC pay dividends?
Abingdon Health PLC does not currently pay dividends.
What is Abingdon Health PLC’s EPS estimate?
Abingdon Health PLC’s EPS estimate is <0.01.
How many shares outstanding does Abingdon Health PLC have?
Abingdon Health PLC has 252,751,500 shares outstanding.
What happened to Abingdon Health PLC’s price movement after its last earnings report?
Abingdon Health PLC reported an EPS of -0.004 p in its last earnings report, beating expectations of -0.006 p. Following the earnings report the stock price went down -3.03%.
Which hedge fund is a major shareholder of Abingdon Health PLC?
Currently, no hedge funds are holding shares in GB:ABDX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Abingdon Health PLC
Established in 2008 and based in York, United Kingdom, Abingdon Health Plc is a global entity dedicated to the creation, production, and worldwide distribution of diagnostic instruments. Their product line features the AbC-19 Rapid Test, a fast-acting diagnostic for COVID-19 IgG antibodies, alongside various nucleic acid lateral flow immunoassays. They also offer Seralite, a swift lateral flow test for accurately measuring kappa and lambda immunoglobulin free light chains in blood serum. Additionally, their AppDx technology converts any smartphone into an autonomous and adaptable lateral-flow reader. Beyond these offerings, the company provides expert services in lateral flow development and manufacturing, as well as advisory support to firms in the health tech industry. Abingdon Health Plc also engages in a collaborative and co-marketing partnership with Abcam plc.
Technical Analysis
Circassia Pharmaceuticals
―
EKF Diagnostics Holdings
―
Genedrive
―
Omega Diagnostics
―
Renalytix
―